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Background/aims Retinal photography with a non-
mydriatic camera is the method currently employed for
diabetic retinography (DR) screening. We designed this
study in order to evaluate the prevalence and severity of
DR, and associated risk factors, in patients with type 2
diabetes (T2DM) screened in Catalan Primary Health
Care.
Methods Retrospective, cross-sectional, population
based study performed in Catalonia (Spain) with patients
with T2DM, aged between 30 years and 90 years (on 31
December 2012) screened with retinal photography and
whose DR category was recorded in their medical records.
DR was classiﬁed as: no apparent retinopathy (no DR),
mild non-proliferative DR (mild NPDR), moderate NPDR,
severe NPDR, proliferative DR (PDR) and diabetic macular
oedema (DMO). Non-vision threatening DR (non-VTDR)
included mild and moderate NPDR; VTDR included severe
NPDR, PDR and DMO. Clinical data were obtained
retrospectively from the SIDIAP database (System for
Research and Development in Primary Care).
Results 108 723 patients with T2DM had been
screened with retinal photography. The prevalence of any
kind of DR was 12.3% (95% CI 12.1% to 12.5%). Non-
VTDR and VTDR were present in 10.8% (mild 7.5% and
moderate NPDR 3.3%) and 1.4% (severe NPDR 0.86%,
PDR 0.36% and DMO 0.18%) of the study patients,
respectively.
Conclusions The prevalence of any type of DR in
patients with T2DM screened with retinal photography
was lower when compared with earlier studies.
INTRODUCTION
Diabetic retinopathy (DR) is a major microvascular
complication in diabetics. It particularly affects
patients with type 2 diabetes (T2DM) whose vision
may be threatened by diabetic macular oedema
(DMO) and proliferative DR (PDR). In developed
countries these two conditions are the principal
cause of blindness in adults of working age and are
responsible for a worsening in quality of life.1
The presence and severity of DR is related to car-
diovascular risk factors and, consequently, a greater
incidence of cardiovascular disease.2
Previous studies have shown a considerable vari-
ation in DR prevalence. Factors such as population
characteristics, screening techniques employed
(direct ophthalmological examination or digital
photography) and type of study performed, all
hinder comparisons among studies. Depending on
the country, the prevalence rate of direct ophthal-
mological screening ranges from 40.3% in the
study by Kempen et al;3 34.6% in the meta-analysis
by Yau et al;4 33.2% in the study by Wong et al;5
to 27.9% in the work from Ruta et al.6 DR preva-
lence in Spain also differs according to the authors.
The results vary from 20.9% to 26.1%.7 8
In studies that employ retinal photography in DR
screening, prevalence also differs: 19% in the UK9
(patients with recently diagnosed T2DM), 29% in
the USA,10 34.6% in Sweden,11 and in the study
carried out by Ruta et al6 in developing and devel-
oped countries between 10.1% and 48.1%. The
variations observed among the countries could be
explained by the screening techniques employed
(direct ophthalmological examination or digital
photography) and the type of study performed.
Factors such as these plus distinct methodologies
and population characteristics all hinder compari-
sons among studies.
In spite of an overall increase in T2DM preva-
lence in Spain12 and abroad,13 a decrease in DR
prevalence, particularly vision threatening DR
(VTDR), has been observed.14 This reduction
could be a result of increased care for patients with
diabetes and an earlier detection of T2DM and
DR,15 the time of progression of diabetes1; poor
control of glycaemia,16 blood pressure,16 dyslipi-
daemia;17 and higher levels of the urinary albumin
to creatine ratio (UACR)18 have been identiﬁed as
risk factors for the onset and progression of DR.
Hyperglycaemia plays a key role in this process;19
and a strict glycaemic control is recommended, par-
ticularly during the initial phases of the disease. In
addition, the control of blood pressure20 and
regular examinations of the ocular fundus are
advised to diminish DR severity and incidence.
It is important to be aware of DR prevalence as it
is a reliable indicator of microvascular complications
and the impact that a good control of the disease can
have on health results. However, the DR prevalence
ﬁgures published in the literature do not correspond
to those we have observed in primary healthcare clin-
ical practice; an issue that can have repercussions on
the correct planning and orientation of resources.
This study was performed in order to observe the
prevalence of DR, and its associated risk factors, in
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patients with T2DM screened with retinal photography, and
whose DR category was recorded in their medical records, at the
Catalonian primary healthcare services (Spain).
MATERIALS AND METHODS
Study, design, settings and population
A population-based, descriptive study was performed in
Catalonia (Spain) with patients with T2DM. Catalonia is a
region in the north-east of Spain and has a public health system
that covers 100% of the population. Most inhabitants (70%)
concentrate in urban areas. All patients aged 30–90 years with a
diagnosis of T2DM (International Classiﬁcation of Diseases 10
codes E11 and E14) before 31 December 2012 were included.
Of a total of 3 755 038 individuals aged 30–90 years, 329 419
patients with T2DM (8.8%) were identiﬁed and 108 723 (33%)
had been screened with retinal photography and all study vari-
ables recorded in the electronic medical record between 1
January 2008 and 31 December 2012.
Information for this study came from the SIDIAP (System for
Research and Development in Primary Care) an electronic data-
base containing all the patients’ medical records. The SIDIAP
includes data from the primary healthcare electronic medical
records named e-CAP (ECAP) on demographic information,
appointment dates with doctors and nurses, clinical diagnoses,
clinical variables, prescriptions written, referrals to specialists
and hospitals, results from laboratory tests, and medication sold
by pharmacies. The quality of SIDIAP data has been previously
documented, and the database has been widely used to study
the epidemiology of a number of health outcomes.21
Assessment of DR
The use of retinal photography for the detection of DR has
been validated.22 Digital colour images are captured from each
eye and the severity of DR is categorised according to the inter-
national clinical DR severity scales recommended by the Global
Diabetic Retinopathy Project Group23 as: no apparent retinop-
athy (no DR), mild non-proliferative DR (mild NPDR), moder-
ate NPDR, severe NPDR, proliferative DR (PDR) and DMO.
All patients should have had at least one fundus photo recorded.
In the case of patients having more than one retinal photograph
between 1 January 2008 and 31 December 2012, the last one
was used for analysis. Each patient was given a DR according to
the worst eye. We took two digital colour images from each eye:
one 45° centred midway between the macula and the optic disc
and the other centred on the macula. In our study, retinal pho-
tography was performed by trained personnel using a non-
mydriatic camera. Subsequently, in the primary healthcare
centre, a family physician trained in reading eye fundus images
registered the result in the patient’s medical records.
Measures of kidney function
Serum creatine levels and UACR were determined and the fol-
lowing deﬁnitions established: normoalbuminuria (UACR
<30 mg/g), microalbuminuria (UACR 30–299 mg/g), and
macroalbuminuria (UACR ≥300 mg/g). The estimated glomeru-
lar ﬁltration ratio (eGFR) was calculated according to the
Modiﬁcation of Diet in Renal Disease equation.
Clinical variables
The following data were obtained from each patient: age, gender,
age at diagnosis of diabetes, duration of diabetes and glycated
haemoglobin levels (A1C). Cardiovascular risk factors including
body mass index, blood lipids, total cholesterol, low density lipo-
protein cholesterol, high density lipoprotein (HDL) cholesterol,
non-HDL cholesterol, blood pressure (systolic and diastolic),
pulse pressure and smoking status according to the last condition
registered before 31 December 2012, were collected. Data for
clinical variables were gathered from the 15 months prior to the
cut-off date with the exception of blood pressure, pulse pressure
and body mass index, which were obtained from the previous
12 months. Additional data was gathered on medication.
Statistical analysis
DR prevalence was calculated assuming a binominal distribution
on which the CI was based. Patient characteristics were com-
pared according to DR presence and severity by analysis of vari-
ance (ANOVA) for the continuous variables and Pearson’s
χ2 test for the categorical ones. The level of statistical signiﬁ-
cance was set at p<0.05. All calculations were performed with
StataCorp V.13.0 (Stata Statistical Software, College Station,
Texas, USA: StataCorp LP).
RESULTS
In our study 108 723 T2DM had been screened with retinal
photography and their DR category recorded in their medical
records.
The overall prevalence of any DR was 12.2% (CI 12.1% to
12.5%): 7.5% mild NPDR, 3.3% moderate NPDR, 0.86%
severe NPDR, 0.36% PDR. DMO was present in 0.18% of the
patients alone or associated with other DR lesions. Prevalence
(ﬁgure 1) of VTDR and non-VTDR was 1.4% and 10.8% (CI
1.4% to 1.5%), respectively. Table 1 shows the characteristics of
the participants with and without retinal photography screening.
The group without retinal photography was older (69.4 years vs
66.9 years), had a shorter T2DM progression time (7.5 years vs
7.8 years), was diagnosed with T2DM at an older age (61.9
years vs 59.2 years), had a higher percentage of eGFR <60 mL/
min/1.73 m2 (22.9 vs 19.7), and higher levels of UACR (45.4
mg/g vs 36.1 mg/g).
Table 2 presents the clinical and metabolic characteristics of
the 108 723 participants with retinal photography and recorded
DR category. Of these 56.2% were men. The mean age was
66.9 (11.0%) years, mean duration of diabetes was 7.8 (5.1%)
years, and mean A1C level was 7.2 (1.3%). In comparison to
patients without DR, those with some kind of DR were older
and with a greater percentage of hypertension. They also had a
longer duration of diabetes, higher A1C levels, higher systolic
blood pressure, lower diastolic blood pressure and higher pulse
pressure. Patients with DR used more insulin than those
without. Participants with some kind of DR had a higher per-
centage of eGFR levels <60 mL/min/1.73 m2 and greater values
of UACR than those without.
Figure 1 Prevalence of diabetic retinopathy.
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Table 3 shows the risk factors associated with DR. The
prevalence of any kind of DR increased with the duration
of diabetes (6.9% <5 years and 23.7% >15 years);
higher A1C levels (8.4%≤7% and 22.9>9%); poorer blood
pressure (10.9%<140/90 and 15.4%≥140/90); and hyperten-
sion (9.1–13.1%). There was a trend towards a lower preva-
lence of any DR in patients with non HDL-cholesterol
≥3.3 mmol/L.







108 723 (33) *P value
Sex, n (%) <0.001
Male 180 198 (54.7) 119 087 (54.0) 61 111 (56.2)
Female 149 221 (45.3) 101 609 (46.0) 47 612 (43.8)
Age (years) (n=329 419) 68.6 (11.7) 69.4 (11.9) 66.9 (11.0) <0.001
BMI (kg/m2, SD) (n=329 419) 30.1 (5.1) 30.1 (5.2) 30.2 (5.0) <0.001
Diabetes time of progress (years) (n=329 419) 7.6 (5.6) 7.5 (5.8) 7.8 (5.1) <0.001
Age of diabetes diagnosis (n=329 419) 61.0 (11.4) 61.9 (11.7) 59.2 (10.7) <0.001
A1C (%) (n=263 690) 7.2 (1.3) 7.2 (1.3) 7.2 (1.3) 0.631
Hypertension, n (%) (n=264 743) 80.4 80.5 80.1 0.003
SBP (mm Hg) (n=279 030) 134.8 (13.2) 135.0 (13.5) 134.5 (12.5) <0.001
DBP (mm Hg) (n=279 030) 75.2 (8.6) 75.0 (8.8) 75.6 (8.3) <0.001
PP (mm Hg) (n=279 030) 59.6 (12.4) 60.0 (12.7) 58.9 (11.9) <0.001
Non-HDL cholesterol (mg/dL) (n=248 610) 137.0 (36.9) 137.0 (37.4) 136.9 (36.0) 0.461
Triglycerides (mg/dL) (n=258 046) 154.5 (102.6) 153.5 (103.3) 156.4 (101.2) <0.001
Creatine (mg/dL) (n=265 898) 0.9 (0.4) 0.9 (0.4) 0.9 (0.3) <0.001
eGFR (mL/min/1.73 m2) <60, n (%) (n=265 898) 57 957 (21.8) 39 431 (22.9) 18 526 (19.7) <0.001
UACR (mg/g) (n=149 526) 41.8 (155.1) 45.4 (163.4) 36.1 (141.3) <0.001
*p Value for comparison of groups with Pearson’s χ2 test for qualitative variables and ANOVA for the quantitative ones. Values are expressed as n (%) and mean (SD).
A1C, glycated haemoglobin; BMI, body mass index; DBP, diastolic blood pressure; DP, digital photography; eGFR, estimated glomerular filtration ratio; PP, pulse pressure; SBP, systolic
blood pressure; UACR, urinary albumin-to-creatine ratio.
Table 2 Clinical and laboratory characteristics of patients without DR, with NPDR, PDR and DMO
Global No DR NPDR PDR DMO P value*
N 108 723 95 336 12 788 400 199
Sex (M), n (%) 61 111 (56.2) 53 642 (56.3) 7137 (55.8) 216 (54.0) 116 (58.3) 0.553
Age (years) (n=108 723) 66.9 (11.0) 66.7 (11.0) 68.5 (10.9) 71.3 (9.7) 69.8 (10.9) <0.001
BMI (Kg/m2) (n=89 610) 30.2 (5.0) 30.2 (5.0) 30.0 (5.1) 30.1 (4.6) 29.5 (4.4) 0.002
Diabetes time of progress (years)
(n=108 723)
7.8 (5.1) 7.5 (4.9) 9.8 (5.9) 10.7 (5.8) 9.6 (5.8) <0.001
Age of diabetes diagnosis (years)
(n=108 723)
59.2 (10.7) 59.2 (10.6) 58.6 (11.2) 60.6 (10.8) 60.2 (11.4) <0.001
A1C (%) (n=95 126) 7.2 (1.3) 7.2 (1.3) 7.7 (1.5) 8.0 (1.6) 7.7 (1.5) <0.001
Insulin treatment, n (%) 18 452 (17.0) 13 338 (14.0) 4819 (37.7) 218 (54.5) 77 (38.7) <0.001
Hypertension, n (%) 87 056 (80.1) 75 645 (79.3) 10 869 (85.0) 364 (91.0) 178 (89.4) <0.001
SBP (mm Hg) (n=97 646) 134.5 (12.5) 134.1 (12.3) 136.9 (13.4) 137.9 (14.2) 138.9 (14.5) <0.001
DBP (mm Hg) (n=97 646) 75.6 (8.3) 75.7 (8.3) 74.7 (8.6) 73.4 (8.7) 74.3 (8.9) <0.001
PP (mm Hg) (n=97 646) 58.9 (11.9) 58.4 (11.7) 62.2 (12.8) 64.5 (12.8) 64.6 (13.0) <0.001
Non-HDL cholesterol (mg/dL)
(n=89 090)
136.9 (36.0) 137.5 (35.8) 132.4 (36.9) 130.1 (35.3) 134.9 (37.7) <0.001
Creatine (mg/dL) (n=93 774) 0.9 (0.3) 0.9 (0.3) 1.0 (0.4) 1.1 (0.5) 1.0 (0.9) <0.001
eGFR (mL/min/1.73 m2), n (%) <0.001
≥60 75 394 (80.3) 66 988 (81.1) 8082 (74.3) 208 (63.4) 116 (69.9)
<60 18 526 (19.7) 15 564 (18.9) 2792 (25.7) 120 (36.6) 50 (30.1)
UACR (mg/g), n (%) <0.001
<30 48 860 (83.0) 43 655 (84.5) 5029 (73.0) 118 (62.1) 58 (59.2)
30–299 8692 (14.8) 7081 (13.7) 1519 (22.1) 58 (30.5) 34 (34.7)
≥300 1294 (2.2) 936 (1.8) 338 (4.9) 14 (7.4) 6 (6.1)
*p Value for comparison of groups with Pearson’s χ2 test for qualitative variables and ANOVA for the quantitative ones.
Values are expressed as n (%) and mean (SD).
A1C, glycated haemoglobin; BMI, body mass index; DBP, diastolic blood pressure; DMO, macular oedema; DR, diabetic retinopathy; eGFR, estimated glomerular filtration ratio; NPDR,
non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PP, pulse pressure; SBP, systolic blood pressure; UACR, urinary albumin-to-creatine ratio.
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DISCUSSION
Our study provides data on the prevalence and severity of DR
in patients with T2DM screened with retinal photography and
whose DR category was recorded in their medical records. A
longitudinal, 10-year follow-up of this cohort is planned in
order to evaluate DR incidence, changes in DR severity and
related complications.
It is well known that, due to the differences in baseline
characteristics, the prevalence of DR is reported to be higher in
clinical studies than in population based ones. We believe the
ﬁgures from the latter to be underestimated. In our study, for
example, patients with glaucoma and cataracts, and those
attended by an ophthalmologist because they had VTDR, did
not usually undergo retinal photography screening in primary
care. In addition, a reduced number of patients who presented a
greater number of complications and worse metabolic control
was attended by an endocrinologist. Moreover in our study, dif-
ferences among patients, with and without retinal photography,
could affect the ﬁnal results of DR prevalence.
In our work, 12.3% (CI 12.1% to 12.5%) of the patients
screened with retinal photography had some kind of DR and
1.4% suffered from VTDR. A DR prevalence rate did not
concur with other studies in which incidence varied between
6% and 27.9%,5 24 and 20.9% and 26.1% in Spain.7 8 A 2007
population-based study carried out in primary care, in which
screening was performed with a direct ophthalmological exam-
ination by a specialist, reported a DR prevalence of 5.8%.21 In
contrast, studies with patients with diabetes screened with
retinal photography observed a DR prevalence ranging from
10.1% to 48.1%.6 The heterogeneity of the studies performed
makes comparisons difﬁcult and disguises the real prevalence of
DR in the T2DM population attended in primary care.
The diabetic population in Catalonia is very well controlled
(from a metabolic point of view) and our population is not a
selected well controlled group. In another study by our group
about metabolic control of glycaemia and cardiovascular risk
factors in patients with T2DM in primary care in Catalonia
(Spain) the mean (SD) A1C value was 7.15% (1.5).21
Better control of T2DM could be the reason for the overall
decrease in the incidence and prevalence of DR.15 In agreement
with prior studies, we observed three major DR risk factors: dia-
betes progression time, A1C levels and blood pressure
control.10 24 It is possible that the total exposure to the gly-
caemic load and cardiovascular risk factors over the years is
reﬂected in the time of diabetes progression. As in other
work,25 we noted that higher A1C values were related to a
greater prevalence of DR while higher levels of non-HDL chol-
esterol to a lesser one. Patients with DR had higher levels of
UACR and lower levels of eGFR than patients without DR.
Diabetes kidney disease and DR are linked to endothelial












N (%) *P value
Sex 0.001
Male 7469 (12.2) 4464 (7.29) 2092 (3.42) 581 (0.95) 216 (0.35) 116 (0.19)
Female 5918 (12.4) 3680 (7.71) 1608 (3.36) 363 (0.76) 184 (0.38) 83 (0.17)
Total 13 387 (12.3) 8144 (7.48) 3700 (3.39) 944 (0.86) 400 (0.36) 199 (0.18)
Diabetes time duration (years) <0.001
<5 2420 (6.9) 1580 (4.50) 607 (1.73) 146 (0.42) 47 (0.14) 40 (0.11)
5–9 5907 (12.5) 3633 (7.68) 1623 (3.44) 396 (0.84) 170 (0.36) 85 (0.18)
10–15 3083 (17.2) 1847 (10.31) 851 (4.74) 221 (1.23) 121 (0.68) 43 (0.24)
>15 1977 (23.7) 1084 (12.99) 619 (7.43) 181 (2.17) 62 (0.74) 31 (0.37)
A1C (%) <0.001
≤7.0 4360 (8.4) 2912 (5.61) 1042 (2.01) 236 (0.45) 99 (0.19) 71 (0.14)
>7.0 to <7.9 3193 (13.3) 1933 (8.05) 918 (3.82) 215 (0.90) 92 (0.38) 35 (0.15)
8 to 9 1868 (18.4) 1064 (10.47) 560 (5.52) 150 (1.48) 67 (0.66) 27 (0.27)
>9 2026 (22.9) 1084 (12.25) 650 (7.35) 191 (2.16) 71 (0.80) 30 (0.34)
Insulin treatment <0.001
No 8273 (9.2) 5370 (5.97) 2146 (2.39) 453 (0.50) 182 (0.20) 122 (0.14)
Yes 5114 (27.7) 2774 (15.03) 1554 (8.42) 491 (2.65) 218 (1.18) 77 (0.42)
Smoking Status 0.182
Smoker 1573 (10.7) 968 (6.58) 441 (3.00) 104 (0.71) 45 (0.31) 15 (0.10)
Past-smoker 3486 (11.9) 2085 (7.13) 991 (3.38) 264 (0.90) 89 (0.30) 54 (0.18)
Never-smoker 8274 (12.9) 5060 (7.89) 2252 (3.51) 568 (0.89) 264 (0.41) 130 (0.20)
Hypertension <0.001
No 1976 (9.1) 1275 (5.87) 516 (2.38) 128 (0.58) 36 (0.17) 21 (0.10)
Yes 11 411 (13.1) 6869 (7.89) 3184 (3.66) 816 (0.93) 364 (0.42) 178 (0.20)
Blood pressure (mm Hg) <0.001
≥140/90 4487 (15.4) 2620 (8.99) 1316 (4.52) 338 (1.16) 143 (0.49) 70 (0.24)
<140/90 7490 (10.9) 4664 (6.79) 2007 (2.92) 484 (0.70) 224 (0.33) 111 (0.16)
No HDL-cholesterol (mmol/L) 0.272
≥3.3 2353 (10.5) 1437 (6.41) 632 (2.82) 183 (0.82) 65 (0.29) 36 (0.16)
<3.3 8390 (12.6) 5105 (7.67) 2366 (3.55) 559 (0.84) 247 (0.37) 113 (0.17)
*p Value for group comparison with Pearson’s χ2 test for qualitative variables and ANOVA for the quantitative ones.
A1C, glycated haemoglobin; DMO, diabetic macular oedema; DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.
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dysfunction; it is possible that microvascular lesions progress in
a parallel manner in the kidney and the eye. Patients with dia-
betes kidney disease should, therefore, be considered at high
risk for DR screening.
In each Primary Health Care Centre of Catalonia, a general
practitioner (GP) trained in reading eye fundus images read the
retinal photography. There is no existing strict quality control on
our screening process, nevertheless, the professionals who
perform and read the retinal photography have previously
received the same regulated and accredited training. Moreover
the professionals who read the fundus may consult with the oph-
thalmologist if they have any doubts. Although the studies that
have evaluated the agreement among GPs and ophthalmologists
in evaluating retinal images in Spain showed a good concord-
ance, we have to accept that the screening of DR performed by
several professionals might have inﬂuenced the ﬁnal results.
Strengths and limitations of the study
Our study has some strengths and limitations. The main
strengths are access to retinal photography screening data, infor-
mation about DR category in the patients’ clinical records, use
of a population based database, and sample size. It is note-
worthy that we were dealing with patients with T2DM attended
in primary care, most of whom followed the corresponding con-
trols. As a consequence, we believe our results to be extremely
relevant for clinical practice. Among our limitations, as it is a
database study, not all patients with T2DM underwent retinal
photography and had the corresponding DR categories regis-
tered in their clinical records.
In addition, patients with VTDR, who were attended by an
ophthalmologist or endocrinologist, could have been poorly
represented.
Another limitation of our study is the duration of diabetes
mellitus in the DR population is higher than observed in the
results. The source of information used in this study is the
SIDIAP, a computerised database containing anonymised patient
records for the 5.8 million people registered with a GP in the
Catalan Health Institute. The SIDIAP contains all data entered
into the ECAP database since it was ﬁrst introduced in some
practices in 1998, but until 2005 the system was not generalised
and used systematically in every Catalan Health Institute prac-
tice. An unknown number of GPs recorded the surgery visit in
the system as the diabetes diagnosis date and not the true date
of diagnosis of diabetes. For that reason we think that the true
duration of diabetes is higher but we think it has not inﬂuenced
the lower prevalence of DR.
CONCLUSIONS
In summary, our study provides data on the prevalence of DR
and VTDR in a sample of 108 723 T2DM participants who
were screened with retinal photography and had their DR cat-
egory registered in their medical records. Our ﬁndings indicate
that the real prevalence of DR and VTDR in T2DM individuals
who were screened with retinal photography is lower than that
published to date in the literature. Nevertheless, it is necessary
to continue with cribbage and good control of risk factors in
order to decrease the prevalence of DR.
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